TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01669330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen fundoplication
Description: Laparoscopic Nissen fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic antireflux surgery ad modum Watson
Description: Laparoscopic anterior fundoplication
Study: NCT02643784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
Study: NCT00860925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active clonidine
Description: Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active clonidine
Description: Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
Study: NCT04941625

Intervention type: DIAGNOSTIC_TEST
Intervention: serum cystatin C
Description: blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: serum cystatin C
Description: blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: serum beta-microglubulin
Description: blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: serum beta-microglubulin
Description: blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: urine
Description: neutrophil gelatinase-associated lipocalin

Intervention type: DIAGNOSTIC_TEST
Intervention: urine
Description: neutrophil gelatinase-associated lipocalin
Study: NCT04611672

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of CA
Description: As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates

Intervention type: DIAGNOSTIC_TEST
Intervention: Assesment of CA only
Description: Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
Study: NCT02349932

Intervention type: OTHER
Intervention: Healthy Adults
Description: The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
Study: NCT03958565

Intervention type: BIOLOGICAL
Intervention: Tyrosine Kinase Inhibitor
Description: Targeted therapy given as standard of care.

Intervention type: DRUG
Intervention: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
Description: Given Q4 weeks as standard of care
Study: NCT00860925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active ASA
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
Study: NCT01655966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D +pegylated interferon + ribavirin
Description: Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon + ribavirin
Description: pegylated interferon 160ug once weekly Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
Study: NCT03873857

Intervention type: DRUG
Intervention: Venetoclax
Description: tablet;oral
Study: NCT01481441

Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue
Description: 2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
Study: NCT05420350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine and Bupropion
Description: Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
Study: NCT00860925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active ASA
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine Placebo
Description: Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Placebo
Description: Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA Placebo
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA Placebo
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
Study: NCT02140827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMP interactive education
Description: The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
Study: NCT03315364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral paclitaxel
Description: Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Study: NCT00361153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam hydrochloride
Description: Welchol tablet 625mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01908842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNX sublingual tablets
Description: Buprenorphine/naloxone sublingual tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNX sublingual tablets
Description: Buprenorphine/naloxone sublingual tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNX sublingual film
Description: Buprenorphine/naloxone sublingual film

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNX sublingual film
Description: Buprenorphine/naloxone sublingual film

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine sublingual tablets
Study: NCT02568423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study: NCT03958565

Intervention type: DRUG
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Given Q12 weeks for bone disease as standard of care
Study: NCT04024761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIML NK
Description: CIML NK cells have enhanced ability to recognize and kill leukemia targets
Study: NCT02138799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: oral
Study: NCT01593267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coil embolization
Description: Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
Study: NCT00460993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lunesta
Description: Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4.
Study: NCT00664170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX-514
Description: 75 mg/m\^2
Study: NCT01593267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clip occlusion
Description: Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
Study: NCT02621684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Activities Model Program for Seniors (CHAMPS)
Description: * Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Activities Model Program for Seniors (CHAMPS)
Description: * Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Activities Model Program for Seniors (CHAMPS)
Description: * Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifetime Total Physical Activity Questionnaire
Description: * Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifetime Total Physical Activity Questionnaire
Description: * Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifetime Total Physical Activity Questionnaire
Description: * Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite (EPIC)
Description: * Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite (EPIC)
Description: * Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expanded Prostate Cancer Index Composite (EPIC)
Description: * Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: International Physical Activity Prevalence Study Environmental Module
Description: -The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
Study: NCT00664170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2
Study: NCT02224664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 5mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 15 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Oral daily doses titrated up to 25 mg QD
Study: NCT04177836

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness intervention
Description: Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
Study: NCT03552783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FFL + Cognitive Behavioral Therapy
Description: Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fathers for a Lifetime (FFL) only
Description: The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~1. Personal responsibility~2. Personal responsibility to your child~3. Responsibility to your family and community
Study: NCT04792229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Viberation
Description: WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Viberation
Description: WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
Study: NCT04544566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product A
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product A
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product A
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product B
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product B
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product B
Description: one new adhesive material which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
Study: NCT03332069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated electro-hyperthermia
Description: Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: High Dose Rate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: High Dose Rate
Study: NCT02455115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating mean arterial pressure
Description: In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating mean arterial pressure
Description: In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating mean arterial pressure
Description: In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
Study: NCT01379209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines
Study: NCT02455115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium ethylenediaminetetraacetic acid
Description: Extraction of 51Cr-EDTA measured for FF and GFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium ethylenediaminetetraacetic acid
Description: Extraction of 51Cr-EDTA measured for FF and GFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium ethylenediaminetetraacetic acid
Description: Extraction of 51Cr-EDTA measured for FF and GFR
Study: NCT01672892

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy
Description: Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.